Summary In the present investigation we have studied the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in ten different human lung carcinoma cell lines, four small cell carcinomas and six non-small cell carcinomas. None of the small-cell lung carcinoma cell lines demonstrated expression of PD-ECGF/TP mRNA. However, four of six of the non-small cell carcinoma cell lines expressed the 1.8 kb PD-ECGF/TP transcript. The cell lines derived from the single squamous cell carcinoma and the two adenocarcinomas expressed the PD-ECGF/TP mRNA, and were found to have the corresponding protein both in cell lysates and conditioned media as determined both by immunoblotting and measurement of thymidine phosphorylase activity. Only one of three studied large cell carcinoma cell lines expressed low levels of PD-ECGF/TP mRNA, but the corresponding PD-ECGF/TP protein was not demonstrated by immunoblotting.
Platelet-derived endothelial cell growth factor (PD-ECGF) was originally characterised as an angiogenesis factor (reviewed by Miyazono et al., 1991) ; it was recently found to have 40% sequence similarity to thymidine phosphorylase of Escherichia coli, and to have thymidine phosphorylase activity (Usuki et al., 1992) . The amino acid sequence of platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP), as deduced from a cDNA clone , revealed that PD-ECGF/TP lacks a signal sequence. PD-ECGF/TP has so far been demonstrated in platelets (Miyazono et al., 1987) , placenta (Usuki et al., 1990) , and in macrophage-like cells of lung and liver (Yoshimura et al., 1990) . Analysis of expression of PD-ECGF/TP protein and mRNA in cell lines revealed that certain epithelial cell lines were positive, including two out of three thyroid carcinoma cell lines .
Human lung cancer can be separated into two major categories, small cell lung cancer (SCLC) and non-SCLC (Bunn, 1992) . The non-SCLC group can be subdivided into three morphological entities, squamous cell carincoma (SQC), adenocarcinoma (ADC) and large cell carcinoma (LCC) (Histological typing of lung tumours, WHO, Geneva 1981) . The distinction between SCLC and non-SCLC is based on discriminative morphology, biochemical marker profile and clinical characteristics (Bunn, 1992) . The SCLC group has high levels of a wide spectrum of neuroendocrine markers (Cuttitta et al., 1985; Gazdar et al., 1985; BaillieJohnson et al., 1985; Soderdahl et al., 1988; Bepler et al., 1987) . The non-SCLC group expresses these neuroendocrine markers at considerably lower levels (Gazdar et al., 1985; Baillie-Johnson et al., 1985; Bunn, 1992) . A heterogeneous mRNA expression for platelet-derived growth factor (PDGF) A-and B-chains, and transforming growth factor (TGF) -a and -P, have been demonstrated in six out of six studied human non-SCLC cell lines (Soderdahl et al., 1988) . The four studied SCLC cell lines were negative for the expression of PDGF and TGF-x or -P (Soderdahl et al., 1988) . The non-SCLC cell lines have been demonstrated to induce a heterogeneous and collagen rich tumour stroma in nude mice xenografts from the non-SCLC cell lines while the SCLC cell lines were devoid of this capacity (Bergh, 1988 Table I . The non-SCLC cell lines grow in monolayer and express epithelial markers and low levels of neuroendocrine markers (Table I ).
Extraction of RNA Total RNA was extracted from cells using a lithium chloride/ urea method described by Auffray and Rougeon (1980) . Cells were homogenised in a solution (3 M lithium chloride, 6 M urea, 0.2% sodium dodecyl sulphate (SDS) and 1 ytI ml-' of Antifoam A (Sigma Chemicals)) and left on ice overnight. The cell homogenate was centrifuged for 5 min at 16,000 g and the pellet was dissolved in a TES-buffer (10 mM Immunoblot analysis Cell cultures were washed with medium and then incubated in serum-free medium for 24 h. The conditioned medium was collected and cells were solubilised in 0.15 M NaCl, 50 mM Tris-HCI pH 7.4, 1 % Triton X-100, 1% deoxycholate, 0. 1% SDS, 10 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 150 kallikrein inhibitor units aprotinin per ml, and centrifuged at 10,000 g for 20 min in order to clarify the samples. Samples were size fractionated by SDS-electrophoresis using gradient gels (10-18% acrylamide) and transferred to a nitrocellulose filter in a buffer consisting of 10% ethanol, 150 mM glycine, and 20 mM Tris-HCI pH 8.4, at 200 mA. In order to block the unspecific binding the filters were incubated in 0.15M NaCl, 10mM Tris-HCl pH 7.4, 5% bovine serum albumin. The filters were then incubated with specific PD-ECGF/TP rabbit antiserum (dilution 1:50) , and washed twice in 0.15 M NaCl, 10 mM Tris-HCI pH 7.4, followed by two washes in 0.15 M NaCl, 10 mM Tris-HCI pH 7.4, 0.05°% Triton X-100.
The filters were then incubated for 30 min with swine antirabbit IgG diluted 1:1000 in 0.15 M NaCl, 10 mM Tris-HCI pH 7.4, and 0.1% bovine serum albumin. After washing as described above, the staining was performed with 100 mg ml-' nitrobluetetrazolium, 40 tg ml-' of 5-bromo-4-chloro-3-indolyl phosphate, 5 mM MgCI2, 0.1 M ethanolamine buffer, pH 9.6.
Thymidine phosphorylase assay Lysates were prepared from the cell lines by freeze-thawing cells 5 times in a buffer consisting of 50 mM Tris-HCI, pH 7.4, 0.15 M NaCl, and centrifuged for 15 min at 10,000g. The cell lysates were incubated for 16 h at 37°C in 5 mM thymidine and 10 mM K3PO4, pH 7.4. At the end of incubation 0.3 ml of the reaction-mix was added to 0.7 ml of 0.5 M NaOH. The conversion of thymidine to thymine was measured spectrofotometrically at 300 nm (Schwartz, 1978) . The thymidine phosphorylase activity found is expressed as the change in optical density at 300 nm (A mOD300) per mg of protein in the cell lysates. 1752), as well as one of the three large cell lung carcinomas (U-1810). There was a marked difference in the amount of PD-ECGF/TP mRNA in the positive cell lines. As seen in Figure 1 , the PD-ECGF/TP probe also hybridised to several mRNA's of different sizes in all studied cell lines except for the thyroid carcinoma cell line. So far three different PD- ECGF/TP transcript sizes have been identified (1.8, 3.0 and 3.2 kb) (Ishikawa et al., 1988; Usuki et al., unpublished results) , and the nature of the cross-hybridising large transcript found in the lung carcinomas is still unknown. In immunoblot analysis using a polyclonal rabbit PD-ECGF/TP antiserum, a 45 kDa PD-ECGF/TP protein was detected in the lysates of H-23, H-125 and U-1752 cells (Figure 2) . However, the protein could not be detected in a cell lysate from U-1810 even though this cell line expressed low amounts of PD-ECGF/TP mRNA. PD-ECGF/TP protein was mainly detected in the cell lysates rather than in the conditioned media which is consistent with the lack of signal sequence in the protein, and with previous results . However, some PD-ECGF/TP immunoreactivity was also found in the conditioned media of the H-23 and H-125 cell lines, the two cell lines with the highest PD-ECGF/TP mRNA level (Figure 2) . The PD-ECGF/TP protein found in the conditioned medium was possibly derived from dying or dead cells. The phosphorylase activity found in cell lysates from the different cell lines correlated well to the expression of PD-ECGF/TP mRNA and protein; a high phosphorylase activity was found in H-23 and H-125 lysates. However, we were unable to detect any thymidine phosphorylase activity in conditioned medium from the cell lines. Our results are summarised in Table II. PD-ECGF/TP seems to be more frequently expressed in more differentiated types of human non-SCLC cell lines. The one exception found in this study is the LCC cell line U-1810. The predominant expression in SQC and ADC may indicate that the PD-ECGF/TP gene is switched on together with other genes related to SQC/ADC differentiation. Thus, PD-ECGF/TP may be a useful marker for the differential diagnosis of lung carcinoma.
The function of PD-ECGF/TP in the human non-SCLC group remains to be elucidated. Expression of transduced PD-ECGF/TP in ras-transformed 3T3 cells leads to a marked increase in the angiogenic response in the nude mouse . It is interesting to speculate that the synthesis of PD-ECGF/TP in lung carcinoma cells contribute in the process of neovascularisation.
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